Nektar Therapeutics, a biopharmaceutical company engaged in the development of differentiated therapeutics with the PEGylation and pulmonary drug development technology platforms. The company has two lead products in development namely Oral NKTR-118 and NKTR-102. It is developing a strong pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. The company is headquartered in California, the US.

On December 31, 2008, the company completed the sale of its assets related to pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation for a purchase consideration of $115.0 million in cash.The company reported revenues of (U.S. Dollars) USD 90.2 million during the fiscal year ended 2008, a decrease of 67.0% from 2007. The operating loss of the company was USD 32.5 million during the fiscal year 2008, as compared to an operating loss of USD 36.1 million during 2007. The net loss of the company was USD 34.3 million during the fiscal year 2008, as compared to a net loss of USD 32.8 million during 2007.